![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Real-life efficacy and safety of Glecaprevir/Pibrentasvir in a large cohort of HCV-infected patients: the MISTRAL study
|
|
|
Reported by Jules Levin
CROI 2019 March 4-7 Seattle
![0320191](../images/032019/032019-11/0320191.gif)
1M. Persico, 1A. Aglitti, 2M. Milella, 3C. Coppola, 4V. Messina, 5E. Claar, 6I. Gentile, 7S. De Gioia, 8P. Pierri, 9L.A. Surace, 10F. Morisco, 11P. Tundo, 12G. Brancaccio, 13G. Serviddio, 14P. Gatti, 15A.P. Termite, 16G.
Di Costanzo, 17B. Caroleo, 18R. Cozzolongo, 12N. Coppola, 19A. Longo, and 1M. Masarone.
1Unità di Medicina Interna ed Epatologia, Università di Salerno; 2Unità di Malattie Infettive, Bari; 3Unità di Medicina Interna ed Epatologia, Gragnano; 4Unità di Malattie Infettive, AORN Caserta; 5Unità di Epatologia, Ospedale Evangelico "Villa Betania", Napoli; 6Unità di Malattie Infettive, Università Federico II, Napoli; 7Unità di Medicina Interna, Ospedale "SS Annunziata",
Taranto; 8Unità di Malattie Infettive ed Epatologia, Ospedale Cotugno, Napoli; 9Centro di Medicina del Viaggiatore e delle Migrazioni, ASP Catanzaro; 10Unità di Gastroenterologia ed Epatologia, Università Federico II, Napoli; 11Unità di Malattie Infettive, Ospedale "S. Caterina Novella", Galatina; 12Unità di Malattie Infettive, Università della Campania "Luigi Vanvitelli",
Napoli; 13Centro CURE, Università di Foggia; 14Unità di Medicina Interna, Ostuni; 15Unità di Medicina Interna, Ospedale di Castellaneta, Taranto; 16Unità di Epatologia, AORN Cardarelli, Napoli; 17Unità di Geriatria, Università Mater Domini, Catanzaro; 18Ospedale S. de Bellis – IRCCS - Castellana Grotte; 19Unità di Malattie Infettive, Ospedale "Perrino", Brindisi
![0320192](../images/032019/032019-11/0320192.gif)
Program Abstract:
Data on the effectiveness and safety of Glecaprevir/Pibrentasvir for the treatment of HCV infection in a 'field-practice' scenario are still scant. This study (MISTRAL: MavIret SouTh italy ReAl Life), currently ongoing, evaluates this therapy in a large cohort of HCV-infected patients from Southern Italy.
All HCV-infected patients, consecutively treated with Glecaprevir/Pibrentasvir at 22 Centers all over Southern Italy were considered. Fibrosis was determined histologically or non-invasively, through liver stiffness measurement. We report here baseline characteristics of patients and available data on end of treatment (EOT). Efficacy of treatment was defined as undetectable HCV-RNA in patients' blood sample obtained twelve weeks after the end of therapy (sustained virological response).
In total, 1178 patients were enrolled (mean age, 60±15 years; 581 males, 49.4%). Most common etiologies were HCV 1b (n=432; 36.8%) and HCV 2 (n=405; 34.5%). One hundred and twenty-three patients (10.5%) were infected from genotype-3 HCV. METAVIR score was F0 in 269 patients (22.9%), F1 in 477 (40.6%), F2 in 209 (17.8%), F3 in 92 (7.8%) and F4 in 103 (8.8%). The wide majority of patients showed normal (CKD1; n=572, 48.7%) or mildly impaired (CKD2; n=472, 40.2%) renal function; 28 subjects had kidney failure (CKD5; 2.4%). Ninety patients (7.7%) were diabetics. Laboratory parameters were as follows: creatinine, 1.02±1.17 mg/dl; bilirubin, 0.76±0.44 mg/dl; hemoglobin, 14.2±1.6 g/dl; platelets, 206874±64111/μl; ALT 45±38 U/L and AST 55±56 U/L. Most patients (n=918; 78.1%) were treatment-naïve. Planned duration of Glecaprevir/Pibrentasvir treatment was 8 weeks for 1067 patients (90.8%), 12 weeks for 102 (8.7%) and 16 weeks for 5 (0.4%). At the time of analysis, data concerning EOT were available for 1178 patients 100% of the total). Almost all of them reached EOT (99.5%). Data on sustained virological response at 12 weeks after EOT are not complete at the time of the present analysis we then here reported data on 885 patients showing a prevalence of 99.3% of SVR. SAE, not related to the drug, were documented in 1% of patients and 8.5% of AE (mostly pruritus).
The large MISTRAL study, conducted in a field-practice scenario, provides a still better prevalence, compared to registration trial, of SVR confirming the extraordinary efficacy and safety of Glecaprevir/Pibrentasvir association also for only 8 weeks treatment. Complete final results will be presented at the CROI meeting.
![0320193](../images/032019/032019-11/0320193.gif)
![0320194](../images/032019/032019-11/0320194.gif)
![0320195](../images/032019/032019-11/0320195.gif)
![0320196](../images/032019/032019-11/0320196.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|